Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EPO patent dispute

Executive Summary

Massachusetts District Court preliminarily rules that Amgen's human recombinant erythropoetin infringes Genetics Institute's patent relating to recombinant DNA production of the substance. Judge William Young said at a Feb. 24 hearing that he would grant the motion of Genetics Institute and Chugai Pharmaceuticals for summary judgment that Amgen infringes their patent. Amgen said it does not plan to "change our strategy with respect to development of human recombinant erythropoeitin" and reiterated its position that Genetics Institute and Chugai are infringing its patent.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel